Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07377994

To Evaluate the Effect of Bacillus Coagulans Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults

This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the effects of a Bacillus coagulans-based probiotic product on gut health, immunological parameters, and overall tolerability in healthy adult participants. The study aims to generate clinical evidence on the role of Bacillus coagulans in maintaining intestinal homeostasis and modulating immune responses under normal physiological conditions.

Gut health will be assessed through both objective and subjective measures. Intestinal inflammation will be evaluated by measuring fecal calprotectin levels, a well-established biomarker of gut mucosal inflammation. Changes in fecal calprotectin from baseline to the end of the intervention period will be compared between the probiotic and placebo groups to determine the impact of the investigational product on gut inflammatory status.

The immunomodulatory effects of the study product will be evaluated by analyzing changes in selected immune and inflammatory markers, including immunoglobulins (IgA, IgG, and IgM). These parameters will be measured at baseline and at the end of the study to assess systemic immune responses associated with supplementation and to compare outcomes between the intervention and placebo groups.

In addition to laboratory-based assessments, participant-reported outcomes related to gut health and immune status will be captured using validated questionnaires, including the Gut Health Status Questionnaire (GHSQ) and the Immune Status Questionnaire (ISQ). These tools will be used to evaluate perceived overall relief and changes in gastrointestinal and immune-related well-being over the course of the study.

Safety and tolerability of the Bacillus coagulans-based product will be evaluated throughout the study duration by monitoring adverse events and other safety parameters in both the intervention and placebo groups, ensuring suitability of the product for use in a healthy population.

Participants will be instructed to consume the assigned study product twice daily, once in the morning and once in the evening after meals, for the duration of the intervention period. Compliance with study product intake will be documented by participants in a subject diary.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Healthy Subjects (HS)

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Advanced Gastro Care

Bangalore, Karnataka, 560018, India

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, aged between 18 and 50 years.
  • Female participants are either not of childbearing potential, or females of childbearing potential agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
  • In good general health, as determined by medical history, laboratory analysis, and physical examination performed by the study physician.
  • Willing to provide fecal samples as per the study requirements.
  • Willing to participate voluntarily and provide written informed consent.

Exclusion criteria

  • Women who are pregnant or lactating.
  • Subjects who are taking Antibiotic treatment.
  • Subjects suffering from Gastrointestinal disease.
  • Subjects suffering from Diabetes.
  • Subjects suffering from Chronic/iatrogenic Immunodeficiency.
  • Subjects suffering from Abnormal blood pressure.
  • Subjects who are allergic to ingredients of the study Product.
  • Subjects who are Smoker or alcoholic.
  • Subjects who have participated prior in conflicting clinical trial or have participated in the trial over the last 3months.
  • Women who are pregnant, breastfeeding, or planning to become pregnant.
  • Daily use of supplements that contain probiotics or prebiotics within 30 days prior to screening or during study.
  • Subjects with medical conditions affecting immune status (e.g., rheumatoid arthritis, heart failure, hepatitis C, HIV) or taking medications that may impact the immune system, such as antibiotics, antimicrobials, or probiotic sachets.
  • Any surgical treatment within the previous three months or planned during the study.
  • Any subject, in the principal investigator's opinion, not considered suitable for enrolment.

Treatment and study plan

Probiotic (Bacillus Coagulans)

Dietary Supplement

Experimental

Placebo

Other

Placebo

Primary outcomes

  1. Change in fecal calprotectin levels from baseline to the end of the study,

    Time frame: Baseline to Week 8 (or end of study)]

    Fecal calprotectin concentration (µg/g) will be measured at baseline and at the end of the study. The change from baseline will be analyzed.

Secondary outcomes

  1. Changes in immunological markers (IgA, IgG, IgM) between baseline to the end of study

    Time frame: Baseline to week 8 (end of the study)

    Immunological markers (IgA, IgG, IgM) will be measured at baseline and at the end of the study. The change from baseline will be analyzed

  2. Change in Gut Health Status Questionnaire (GHSQ) Total score from baseline to End of the Study

    Time frame: Baseline to week 8 (End of the Study)

    The Gut Health Status Questionnaire (GHSQ) Total score will be assessed at the baseline and at the end of the study. The change from baseline will be analyzed

  3. Change in Immune Status Questionnaire (ISQ) Total Score from Baseline to End of the Study

    Time frame: Baseline to week 8 (End of the Study)

    The Immune Status Questionnaire (ISQ)total score will be assessed at the Baseline and at the end of the study. The change from Baseline will be analyzed

Sponsors and collaborators

Lead sponsor

Bioagile Therapeutics Pvt. Ltd.

Industry

Registry information

Official study title

A Prospective, Randomized, Double-blinded, Placebo-controlled Parallel Group-Clinical Trial Assessing Gut Health and Immunomodulatory Effects of Bacillus Coagulans Based Product in Healthy Adults

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 30, 2026
Registry last updated
Jan 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.